ZGNX 1.38 0.00 0.00 67,300 1.38 1.40
Market Updates on Pharma Stocks - Zogenix, Valeant Pharma Intl., Sanofi, Novartis, and Ampio Pharma
10 minutes ago - DJNF
LONDON, May 12, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Sanofi (NYSE: SNY), Novartis A.G. (NYSE: NVS), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research report on Zogenix can be accessed at http://get.Investor-Edge.com/pdf/?c=Zogenix&a...amp;s=ZGNX. The US markets on Monday, May 11, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 18,105.17, down 0.47% and the NASDAQ Composite closed at 4,993.57, down 0.20%. The S&P 500 finished the session 0.51% lower at 2,105.33. During the trading session, all the ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 848.25, down 0.03%, whereas the index has advanced 4.60% in the previous three months. Register for your complimentary reports at the links given below.
Zogenix Inc.'s stock lost 1.43%, to close the day at $1.38. The stock recorded a trading volume of 1.53 million shares, below its three months average volume of 3.36 million shares. The company's shares oscillated between $1.36 and $1.41 during the session. Over the last three trading sessions and over the past one month, Zogenix Inc.'s shares have fallen by 0.72% and 7.38%, respectively. However, the stock has advanced 5.34% in the previous three months. The company is trading above its 200-day moving average of $1.34, while the 200-day moving average is below Zogenix Inc.'s 50-day moving average of $1.48. Additionally, the stock has a Relative Strength Index (RSI) of 43.29. Sign up and read the free notes on ZGNX at:
http://get.Investor-Edge.com/pdf/?c=Zogenix&a...amp;s=ZGNX
On Monday, shares in Valeant Pharmaceuticals International Inc. recorded a trading volume of 1.28 million shares, lower than its three months average volume of 2.96 million shares. The stock ended the day at $223.79, which was 0.86% above its previous day's closing of $221.88, and registered an intraday range of $222.05 and $224.97. Shares of the company traded at a PE ratio of 81.40. Valeant Pharmaceuticals International Inc.'s shares have surged 7.85% in the last one month, 36.18% in the previous three months, and 56.38% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $205.28 and $153.73, respectively. Furthermore, shares of Valeant Pharmaceuticals International Inc. have an RSI of 63.94. The complimentary notes on VRX can be downloaded as in PDF format at:
http://get.Investor-Edge.com/pdf/?c=Valeant%2...&s=VRX
Sanofi's stock fell 1.28% to end Monday's session at $49.35. The stock recorded a trading volume of 0.78 million shares, below its three months average volume of 1.44 million shares. The company's shares fluctuated between $49.35 and $49.81 during the session. Sanofi's shares have gained 8.20% since the beginning of 2015 and 2.47% in the past three months. However, the stock has fallen by 0.20% in the previous three trading sessions. The company is trading below its 50-day and 200-day moving averages. Sanofi's 50-day moving average of $50.16 is above its 200-day moving average of $50.06. Additionally, Sanofi has an RSI of 44.73. Register for free on Investor-Edge and access the latest research on SNY at:
http://get.Investor-Edge.com/pdf/?c=Sanofi&am...&s=SNY
On Monday, shares in Novartis A.G. fluctuated between $101.89 and $103.00 before ending the session 0.49% lower at $102.42. The stock reported a trading volume of 0.97 million shares, lower than its three months average volume of 1.44 million shares. Novartis A.G.'s stock has advanced 0.78% in the previous three trading sessions, 0.14% in the last three months, and 10.53% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $101.08 and $95.35, respectively. Moreover, shares of Novartis A.G. have an RSI of 52.42. The complete research on NVS is available for free at:
http://get.Investor-Edge.com/pdf/?c=Novartis&...&s=NVS
Ampio Pharmaceuticals Inc.'s stock finished Monday's session 1.23% lower at $2.40. A total of 0.34 million shares were traded, which was below its three months average volume of 1.16 million shares. The stock vacillated between $2.32 and $2.46 during the session. Over the last one month and over the past three months, Ampio Pharmaceuticals Inc.'s shares have plummeted 71.33% and 57.45%, respectively. However, the stock has advanced 1.69% in the previous three trading sessions. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $5.93 is greater than its 200-day moving average of $4.75. Ampio Pharmaceuticals Inc.'s stock has an RSI of 23.24. Free in depth research on AMPE is available at:
http://get.Investor-Edge.com/pdf/?c=Ampio%20P...amp;s=AMPE
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
/CONTACT: Adam Redford CONTACT PHONE: +852-8191-3972
(END) Dow Jones Newswires
May 12, 2015 09:10 ET (13:10 GMT)
Market Updates on Pharma Stocks - Zogenix, Valeant Pharma Intl., Sanofi, Novartis, and Ampio Pharma
10 minutes ago - DJNF
LONDON, May 12, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Sanofi (NYSE: SNY), Novartis A.G. (NYSE: NVS), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research report on Zogenix can be accessed at http://get.Investor-Edge.com/pdf/?c=Zogenix&a...amp;s=ZGNX. The US markets on Monday, May 11, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 18,105.17, down 0.47% and the NASDAQ Composite closed at 4,993.57, down 0.20%. The S&P 500 finished the session 0.51% lower at 2,105.33. During the trading session, all the ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 848.25, down 0.03%, whereas the index has advanced 4.60% in the previous three months. Register for your complimentary reports at the links given below.
Zogenix Inc.'s stock lost 1.43%, to close the day at $1.38. The stock recorded a trading volume of 1.53 million shares, below its three months average volume of 3.36 million shares. The company's shares oscillated between $1.36 and $1.41 during the session. Over the last three trading sessions and over the past one month, Zogenix Inc.'s shares have fallen by 0.72% and 7.38%, respectively. However, the stock has advanced 5.34% in the previous three months. The company is trading above its 200-day moving average of $1.34, while the 200-day moving average is below Zogenix Inc.'s 50-day moving average of $1.48. Additionally, the stock has a Relative Strength Index (RSI) of 43.29. Sign up and read the free notes on ZGNX at:
http://get.Investor-Edge.com/pdf/?c=Zogenix&a...amp;s=ZGNX
On Monday, shares in Valeant Pharmaceuticals International Inc. recorded a trading volume of 1.28 million shares, lower than its three months average volume of 2.96 million shares. The stock ended the day at $223.79, which was 0.86% above its previous day's closing of $221.88, and registered an intraday range of $222.05 and $224.97. Shares of the company traded at a PE ratio of 81.40. Valeant Pharmaceuticals International Inc.'s shares have surged 7.85% in the last one month, 36.18% in the previous three months, and 56.38% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $205.28 and $153.73, respectively. Furthermore, shares of Valeant Pharmaceuticals International Inc. have an RSI of 63.94. The complimentary notes on VRX can be downloaded as in PDF format at:
http://get.Investor-Edge.com/pdf/?c=Valeant%2...&s=VRX
Sanofi's stock fell 1.28% to end Monday's session at $49.35. The stock recorded a trading volume of 0.78 million shares, below its three months average volume of 1.44 million shares. The company's shares fluctuated between $49.35 and $49.81 during the session. Sanofi's shares have gained 8.20% since the beginning of 2015 and 2.47% in the past three months. However, the stock has fallen by 0.20% in the previous three trading sessions. The company is trading below its 50-day and 200-day moving averages. Sanofi's 50-day moving average of $50.16 is above its 200-day moving average of $50.06. Additionally, Sanofi has an RSI of 44.73. Register for free on Investor-Edge and access the latest research on SNY at:
http://get.Investor-Edge.com/pdf/?c=Sanofi&am...&s=SNY
On Monday, shares in Novartis A.G. fluctuated between $101.89 and $103.00 before ending the session 0.49% lower at $102.42. The stock reported a trading volume of 0.97 million shares, lower than its three months average volume of 1.44 million shares. Novartis A.G.'s stock has advanced 0.78% in the previous three trading sessions, 0.14% in the last three months, and 10.53% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $101.08 and $95.35, respectively. Moreover, shares of Novartis A.G. have an RSI of 52.42. The complete research on NVS is available for free at:
http://get.Investor-Edge.com/pdf/?c=Novartis&...&s=NVS
Ampio Pharmaceuticals Inc.'s stock finished Monday's session 1.23% lower at $2.40. A total of 0.34 million shares were traded, which was below its three months average volume of 1.16 million shares. The stock vacillated between $2.32 and $2.46 during the session. Over the last one month and over the past three months, Ampio Pharmaceuticals Inc.'s shares have plummeted 71.33% and 57.45%, respectively. However, the stock has advanced 1.69% in the previous three trading sessions. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $5.93 is greater than its 200-day moving average of $4.75. Ampio Pharmaceuticals Inc.'s stock has an RSI of 23.24. Free in depth research on AMPE is available at:
http://get.Investor-Edge.com/pdf/?c=Ampio%20P...amp;s=AMPE
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
/CONTACT: Adam Redford CONTACT PHONE: +852-8191-3972
(END) Dow Jones Newswires
May 12, 2015 09:10 ET (13:10 GMT)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
